Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Total Liabilities (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Total Liabilities for 8 consecutive years, with $56.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 15.62% to $56.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.8 million through Dec 2025, down 15.62% year-over-year, with the annual reading at $50.8 million for FY2025, N/A changed from the prior year.
  • Total Liabilities for Q4 2025 was $56.8 million at Outlook Therapeutics, up from $50.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $67.3 million in Q4 2024, with the low at $50.8 million in Q3 2025.